|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-1-24
|
|
pubmed:abstractText |
OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1464-8431
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
547-54
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17243491-Animals,
pubmed-meshheading:17243491-Clinical Trials, Phase I as Topic,
pubmed-meshheading:17243491-Clinical Trials, Phase II as Topic,
pubmed-meshheading:17243491-Clusterin,
pubmed-meshheading:17243491-Drug Evaluation, Preclinical,
pubmed-meshheading:17243491-Female,
pubmed-meshheading:17243491-Humans,
pubmed-meshheading:17243491-Male,
pubmed-meshheading:17243491-Neoplasms,
pubmed-meshheading:17243491-Oligodeoxyribonucleotides, Antisense,
pubmed-meshheading:17243491-Structure-Activity Relationship
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
|
|
pubmed:affiliation |
University of Regensburg, Institute of Clinical Chemistry and Laboratory Medicine, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany. gerd.schmitz@klinik.uni-regensburg.de
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Review
|
